March 24 - Kyodo News reported.JapanResearch published today by the National Cancer Institute says that using generative formulas when writing draft reports for clinical trials of new drugs AI The time required could be significantly reduced. Of the 119 drafts produced.Eighty percent of them can be finalized with only minor revisions by hand.. The center said that by improving the efficiency of the procedures, it could shorten the time it takes for a drug to be approved for use in patients.
Kenichi Nakamura, head of the international development department at the center's Central Hospital, said the AI could also be used to produce for patients enrolled in the trialEasy-to-understand explanatory documentsBefore that, the production of reports was outsourced to professional writers. Previously, the production of reports, for example, had to be outsourced to professional writers, and the process from solicitation to submission to pharmaceutical companies and regulatory authorities requiredhalf a yeartime, each copy costing as much asAbout 5 million yen(Note: The current exchange rate is approximately RMB 243,000).
Japan's National Cancer Research Center and Rozetta, a Tokyo-based company engaged in AI translation, reportedly developed an AI software that inputs theClinical trial proposal and data analysis results after theThe automatic generation of chapters and writing of reports is also reduced in time tofew daysThe results of the completion assessment showed that 50 per cent were "almost ready to use" and 30 per cent were "fine-tuned to use". The results of the completion assessment showed that 50 per cent were "almost ready for use" and 30 per cent were "ready for use after fine-tuning".
